An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

What's the BIOSECURE Act? Why is Merck nonchalant about Summit's Keytruda rival? What did Roivant buy from Bayer? We answer ...

Finnish drugmaker Orion wants to boost sales in the United States on the back of the success of its prostate cancer drug Nubeqa, which it is developing jointly with German partner Bayer , Orion's ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

Radiopharmaceuticals have been used to treat patients with prostate cancer for decades, but experts say there is more to learn about these agents.

After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. | After a ...

Healthcare systems account for nearly 5% of all global emissions with the majority falling under Scope 3 emissions. The ...

DelveInsight's Hormone Replacement Therapy Market Insights report provides the current and forecast market analysis, ...

DelveInsight's Prostate Cancer Diagnostics Market Insights report provides the current and forecast market analysis, ...

Investigators compared outcomes between patients with stage II/III colon cancer given adjuvant aspirin and those given ...

European stocks are up firmly on Friday and look set to end the week on a positive note, amid renewed optimism over China's stimulus ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.